ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LEGN / insiders
EWTX (41) INDV (51) LQDA (36) ARQT (54) ⌘ Pro Terminal →

Legend Biotech Corporation (LEGN) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$21.10 -2.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.97

Legend Biotech Corporation (LEGN) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $4.21B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LEGN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LEGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Legend Biotech Corporation (NASDAQ: LEGN) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $21.10 (-2.45% 1D, market cap $4.21B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, LEGN ranks #162 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LEGN compare to EWTX and INDV in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LEGN carries a Roarable C- (60/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, EWTX (Edgewise Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -31.9%, cap $4.22B) and INDV (Indivior Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E 19.8x, ROIC 62.2%, cap $4.17B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LEGN?
▼

For Legend Biotech Corporation (LEGN), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs and sector rank #162 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $20.97 (-0.63%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 2.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 60/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.4% avg 90D alpha vs SPY • 53.5% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C-
025507510060
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C
Cash (11)Whales (11)SEC (16)Macro (10)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+0.9% Base Target
$39 Bull$21 Base$17 Bear
📬 FREE LEGN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LEGN)Realized 20D OHLCV Swing Band: ±11%
Deterministic 5-Pillar Attribution (60/100 Composite)
🔍 WHY LEGN SCORES 60/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (27% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+12/20 pts (20% of score)

SEC Form 4 / 13F Thermometer: 60% Net Buy • Cannibal Buyback (-1.24% YoY Shares)

▼ #1 Drag / Risk Factor: Macro Regime Fit10/20 pts (-10 pt drag)

Macro rate sensitivity & RSI-14 (59.2) create a -10 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
52
Grade C-$19.04-2.2% Next Q
Q2 (-2Q)
55
Grade C$18.63+20.9% Next Q
Q3 (-1Q)
57
Grade C$22.53-6.3% Next Q
Current
60
Grade C-$21.10+0.4% Hist 90D α
Trajectory: C- (52) → C- (60)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LEGN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 60/100 (C-) score, LEGN faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($19.60) or 200D SMA ($22.13) invalidates the momentum regime and cuts Target Base ($21.29) toward Bear Floor ($16.61).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LEGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LEGN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 60%NO 40%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

LEGN Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (LEGN)

No recent open-market Form 4 cluster sales or emergency dumps flagged on LEGN. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (LEGN Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LEGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.38%📐 HORIZONTAL RANGE
2026-11-03O $22.30H $22.30L $21.10C $21.10VOL 2.19M
RES: $22.95SUP: $15.25SMA50: $19.60SMA200: $22.13
$38.94$32.96$26.97$20.99$15.00RES $22.95SUP $15.25$21.102026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LEGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LEGN Butterfly Map → + Track LEGN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
25.3%/yr Implied 5Y Growth

vs. +9.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LEGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LEGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LEGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LEGN)

Health Care Rank #162 of 1015 ⚔️ EWTX vs LEGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LEGN vs. EWTX, INDV, LQDA, ARQT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Legend Biotech Corporation (LEGN) ranks #162 by composite RQD confidence (60/100, grade C-) and #174 by equity capitalization ($4.21B). Within this direct 5-issuer industry benchmark cohort, INDV leads on earnings valuation at 19.8x trailing P/E, while INDV leads on capital efficiency and profitability with 62.2% ROIC and 80.2% gross margin. LEGN currently leads its immediate peer cohort in composite quantitative strength at 60/100 (C-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LEGN ACTIVE
Legend Biotech Corporation
C- 60/100 32.8x — 9.9% -2.45% $4.21B Benchmark Subject
EWTX
Edgewise Therapeutics Inc.
D- 41/100 — — -31.9% -2.03% $4.22B /ewtx-vs-legn →
INDV
Indivior Pharmaceuticals Inc.
D 51/100 19.8x 80.2% 62.2% +0.34% $4.17B /indv-vs-legn →
LQDA
Liquidia Corporation
D- 36/100 — — -12.6% -7.12% $4.03B /lqda-vs-legn →
ARQT
Arcutis Biotherapeutics Inc.
D+ 54/100 — 90.2% -3.0% -2.53% $4.03B /arqt-vs-legn →

2. LEGN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Legend Biotech Corporation (LEGN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $4.21B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. LEGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LEGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Legend Biotech Corporation (NASDAQ: LEGN) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $21.10 (-2.45% 1D, market cap $4.21B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, LEGN ranks #162 in composite RQD confidence.

How does LEGN compare to EWTX and INDV in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LEGN carries a Roarable C- (60/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, EWTX (Edgewise Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -31.9%, cap $4.22B) and INDV (Indivior Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E 19.8x, ROIC 62.2%, cap $4.17B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LEGN?

For Legend Biotech Corporation (LEGN), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs and sector rank #162 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LEGN trading relative to its 50-day, 200-day, and 52-week technical levels?

LEGN last traded at $21.10 (-2.45% on volume of 1,133,847 shares), positioning the stock +7.65% above its 50-day simple moving average ($19.60) and -4.65% below its 200-day simple moving average ($22.13). Across its 52-week range of $16.24 to $37.50, LEGN sits at the 22.9% percentile with a 14-day RSI of 59.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.0% ($18.78 to $23.42).

Direct Sub-Reports: LEGN RQD Cockpit LEGN 12M Forecast LEGN Earnings & Move LEGN Dividends & DRIP LEGN Insiders & 13F LEGN Whale Options LEGN Profit Sankey LEGN News & Why
ROARABLE RATING BRIEF • RQD 60/100 (C-) ✓ SEC XBRL & RQD VERIFIED

LEGN — Legend Biotech Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Legend Biotech Corporation (LEGN) earns a live Roarable RQD composite score of 60/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $21.10 (-2.45% 1D, market capitalization $4.21B).

  • Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of 9.9%, gross margin of —, operating margin of 13.9%, and free cash flow yield of 2.21%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (16/20): Incorporates a 1.04x equity beta, Altman Z-Score of 3.74, Piotroski F-Score of 8/9, and Debt/Equity of 0.39x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Legend Biotech Corporation is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It carries a market capitalization of $4.3B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C- • RQD 60/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of 2.21% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $16.24 – $37.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 32.8x trailing P/E and 21.0x EV/EBITDA against 13.9% operating margins and a 1.04x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream links, sector correlations, or 2nd-order bottlenecks are recorded. — for supplier, partner, or customer dependencies.

  • Key Question #1: Can LEGN sustain or expand its 13.9% operating margin and 9.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (2.21% FCF yield) strengthen balance-sheet liquidity (Altman Z-Score 3.74) toward the $37.50 52-week high?
  • Key Question #3: How sensitive is LEGN's 30.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.04x)?

LEGN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Legend Biotech Corporation (LEGN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LEGN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LEGN Bull vs. Bear Conversation Board — What's Your Call at $21.10?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LEGN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LEGN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $27.04 (+25.0%)
📌 Pinned Debate

Balance-sheet strength (Altman Z 3.74, Piotroski F 8/9, Debt/Equity 0.39) scores highest among the RQD pillars.

Don't sleep on LEGN's setup in Health Care. Balance-sheet strength (Altman Z 3.74, Piotroski F 8/9, Debt/Equity 0.39) scores highest among the RQD pillars.. Beta of 1.04 means it moves fast when momentum turns, and the 5-pillar RQD gauge (60/100) backs up the fundamental quality.

ArenaChamp_24 🐂 BULL

@ShortSeller_Dan Fair point on 32.8x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $18.60 (-14.0%)
Spot @ $21.63

Valuation is demanding at 32.8 TTM P/E with a thin 2.21% FCF yield and modest 9.9% ROIC.

Fading this rally in LEGN at $21.63. Valuation is demanding at 32.8 TTM P/E with a thin 2.21% FCF yield and modest 9.9% ROIC.. With a beta of 1.04 and the stock sitting at $21.63 (52-wk range $16.24–$37.50), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%